Our CEO comment on new research findings in the Alzheimer field

“We see that this outcome proves and further strengthens the company's research because we already have indications that specificity is important to be able to treat the disease where Alzinova is unique in the field with a vaccine that can target the toxic accumulations of amyloid-beta to a greater extent than others. The vaccine that we have in the phase 1 study will probably be more effective, safer, and simpler as well as from a health economic perspective better due to high specificity.”